Related Experiment Videos
Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor
Young-Hwa Goo1, Soon-Young Na, Hao Zhang
1Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
Activating signal cointegrator-2 (ASC-2), a cancer-amplified transcription coactivator of nuclear receptors and numerous other transcription factors, was previously shown to contain two LXXLL motifs, each of which interacts with a distinct set of nuclear receptors. In this work, we showed that ASC-2 has an indirect, separate binding site for androgen receptor (AR). Interestingly, this region overlapped with the direct interaction interfaces with the tumor suppressor retinoblastoma (Rb). Although ASC-2 alone stimulated AR transactivation in cotransfections of HeLa cells, ectopic expression of Rb effected ASC-2 to act as a transcription coactivator of AR in Rb-null Saos2 cells. These results, along with the previous report in which AR was shown to directly interact with Rb (Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., Hsiao, P., Wang, C., Su, C., and Chang C. (1998) Biochem. Biophys. Res. Commun. 248, 361-367), suggest that the AR-ASC-2 interactions in vivo may involve Rb. Thus, ASC-2 appears to contain at least three distinct nuclear receptor interaction domains.
Insights
Activating signal cointegrator-2 (ASC-2) interacts with the androgen receptor (AR) indirectly, with retinoblastoma (Rb) potentially mediating this interaction. ASC-2 demonstrates multiple nuclear receptor interaction domains, including a novel one for AR.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Activating signal cointegrator-2 (ASC-2) is a cancer-amplified coactivator for nuclear receptors.
- ASC-2 possesses two known LXXLL motifs for nuclear receptor interaction.
- Androgen receptor (AR) is a key nuclear receptor implicated in various cellular processes.
Purpose of the Study:
- To investigate the interaction between ASC-2 and androgen receptor (AR).
- To identify novel binding sites and mechanisms of ASC-2-mediated AR transactivation.
- To explore the role of retinoblastoma (Rb) in the ASC-2 and AR interaction.
Main Methods:
- Co-transfection assays in HeLa and Rb-null Saos2 cells.
- Analysis of ASC-2 interaction interfaces with AR and Rb.
- Investigating the effect of ectopic Rb expression on ASC-2-mediated AR transactivation.
Main Results:
- ASC-2 exhibits an indirect binding site for AR, separate from its LXXLL motifs.
- This AR binding region on ASC-2 overlaps with its direct interaction interface for Rb.
- Retinoblastoma (Rb) expression facilitates ASC-2's coactivation of AR in Rb-null cells.
Conclusions:
- ASC-2 contains at least three distinct nuclear receptor interaction domains.
- The interaction between ASC-2 and AR in vivo may be mediated by Rb.
- This suggests a complex regulatory mechanism for AR transactivation involving ASC-2 and Rb.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway